Touchon J, Bertin L, Pilgrim A J, Ashford E, Bès A
Department of Neurology, Hôpital Arnaud de Villeneuve, Montpellier, France.
Neurology. 1996 Aug;47(2):361-5. doi: 10.1212/wnl.47.2.361.
We compared the efficacy and safety of subcutaneous (SC) sumatriptan (6 mg) with that of dihydroergotamine (DHE) nasal spray (1 mg plus optional 1 mg) in the acute treatment of migraine. Two hundred sixty-six adult migraineurs (International Headache Society criteria) completed a multicenter, double-blind, double-dummy, cross-over study. Patients took SC sumatriptan for one attack and DHE nasal spray for the other in random order. Data from both treatment periods show that at all time points from 15 minutes, SC sumatriptan was significantly better than DHE nasal spray at providing both headache relief (moderate/severe headache improving to mild/none) and resolution of headache. Similarly, SC sumatriptan was superior to DHE nasal spray for the other efficacy end points assessed in the study. Patients reported that both treatments were well tolerated. Adverse events were reported by 43% of patients taking SC sumatriptan and 22% of patients taking DHE nasal spray. These were usually mild and transient. We conclude that subcutaneous sumatriptan has a faster onset of action than DHE nasal spray and provides greater relief of acute migraine symptoms.
我们比较了皮下注射舒马曲坦（6毫克）与双氢麦角胺（DHE）鼻喷雾剂（1毫克加可选的1毫克）在偏头痛急性治疗中的疗效和安全性。266名成年偏头痛患者（符合国际头痛协会标准）完成了一项多中心、双盲、双模拟、交叉研究。患者随机顺序服用皮下注射舒马曲坦治疗一次发作，服用DHE鼻喷雾剂治疗另一次发作。两个治疗期的数据显示，从15分钟起的所有时间点，皮下注射舒马曲坦在缓解头痛（中度/重度头痛改善为轻度/无头痛）和头痛消退方面均显著优于DHE鼻喷雾剂。同样，在该研究评估的其他疗效终点方面，皮下注射舒马曲坦也优于DHE鼻喷雾剂。患者报告称两种治疗的耐受性均良好。服用皮下注射舒马曲坦的患者中有43%报告了不良事件，服用DHE鼻喷雾剂的患者中有22%报告了不良事件。这些不良事件通常轻微且短暂。我们得出结论，皮下注射舒马曲坦的起效速度比DHE鼻喷雾剂更快，能更有效地缓解急性偏头痛症状。
